{"id":499847,"date":"2020-08-01T00:00:00","date_gmt":"2020-07-30T19:48:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=499847"},"modified":"2020-07-30T19:48:01","modified_gmt":"2020-07-30T19:48:01","slug":"adrenoleukodystrophy-emerging-drugs-and-key-players-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/adrenoleukodystrophy-emerging-drugs-and-key-players-delveinsight_499847.html","title":{"rendered":"Adrenoleukodystrophy Emerging drugs and Key Players | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Adrenoleukodystrophy Emerging drugs and Key Players | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Adrenoleukodystrophy Emerging drugs and Key Players | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Adrenoleukodystrophy Pipeline Insight, 2020&#8243; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Adrenoleukodystrophy market. A detailed picture of the Adrenoleukodystrophy pipeline landscape is provided, which includes the disease overview and Adrenoleukodystrophy treatment guidelines.<\/div>\n<p style=\"text-align: justify;\"><span>Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland.<\/span><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/adrenoleukodystrophy-pipeline-insight\" target=\"_blank\">Adrenoleukodystrophy&nbsp;Emerging Therapies<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ol style=\"text-align: justify;\">\n<li>Lenti D: bluebird bio<\/li>\n<li>Leriglitazone: Minoryx Therapeutics, S.L.<\/li>\n<li>MD1003: MedDay Pharmaceuticals<\/li>\n<li>MGTA-456: Magenta Therapeutics<\/li>\n<li>OP-101: Orpheris Inc.<\/li>\n<li>SOM1201: SOM Biotech<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><span>Scope of the Report<\/span><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\">The&nbsp;Adrenoleukodystrophy&nbsp;report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em>Adrenoleukodystrophy&nbsp;across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li class=\"ql-align-justify\"><span>It comprises of&nbsp;<\/span><em>detailed profiles of&nbsp;<\/em><span>Adrenoleukodystrophy&nbsp;<\/span><em>therapeutic products<\/em><span>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Detailed&nbsp;<\/span><span>Adrenoleukodystrophy&nbsp;<\/span><em>research and development progress and trial details<\/em><span>, results wherever available, are also included in the pipeline study.<\/span><\/li>\n<li class=\"ql-align-justify\"><em>Coverage of dormant and discontinued pipeline project<\/em><span>s along with the reasons if available across&nbsp;<\/span><span>Adrenoleukodystrophy&nbsp;<\/span><span>.<\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/adrenoleukodystrophy-pipeline-insight\" target=\"_blank\">Request for sample pages<\/a><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/adrenoleukodystrophy-pipeline-insight\" target=\"_blank\">Table of contents<\/a><\/p>\n<p style=\"text-align: justify;\"><span>1. Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2. Adrenoleukodystrophy &nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.1. Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.2. History&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.3. Adrenoleukodystrophy Symptoms<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.4. Causes<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.5.Pathophysiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.6. Adrenoleukodystrophy Diagnosis&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.6.1. Diagnostic Guidelines<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3. Adrenoleukodystrophy &nbsp;Current Treatment Patterns<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.1. Adrenoleukodystrophy Treatment Guidelines<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4. Adrenoleukodystrophy &nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1. In-depth Commercial Assessment<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1.1. Adrenoleukodystrophy &nbsp;companies collaborations, Licensing, Acquisition -Deal Value Trends<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1.1.1. Assessment Summary<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1.2. Adrenoleukodystrophy &nbsp;Collaboration Deals<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1.2.3. Adrenoleukodystrophy &nbsp;Acquisition Analysis<\/span><\/p>\n<p style=\"text-align: justify;\"><span>5. Therapeutic Assessment<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1. Clinical Assessment of Pipeline Drugs&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.1. Assessment by Phase of Development<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.2. Assessment by Product Type (Mono \/ Combination)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.2.1. Assessment by Stage and Product Type<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.3. Assessment by Route of Administration<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.3.1. Assessment by Stage and Route of Administration<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.4. Assessment by Molecule Type<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.4.1. Assessment by Stage and Molecule Type<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.5. Assessment by MOA<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.5.1. Assessment by Stage and MOA<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.6. Assessment by Target<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.6.1. Assessment by Stage and Target<\/span><\/p>\n<p style=\"text-align: justify;\"><span>6. Adrenoleukodystrophy Late Stage Products (Phase-III)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>7. Adrenoleukodystrophy Mid Stage Products (Phase-II)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>8. Early Stage Products (Phase-I)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10. Inactive Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11. Dormant Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12. Adrenoleukodystrophy Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13. Adrenoleukodystrophy &nbsp;Product Profiles<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1. Drug Name: Company&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.1. Product Description<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.1.1. Product Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.1.2. Mechanism of action<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.2. Research and Development<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.2.1. Clinical Studies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.3. Product Development Activities<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.3.1. Collaboration<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.3.2. Agreements<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.3.3. Acquisition&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.3.4. Patent Detail<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.4. Tabulated Product Summary<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.4.1. General Description Table<\/span><\/p>\n<p style=\"text-align: justify;\"><span>14. Adrenoleukodystrophy &nbsp;Key Companies<\/span><\/p>\n<p style=\"text-align: justify;\"><span>15. Adrenoleukodystrophy &nbsp;Key Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>16. Dormant and Discontinued Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.1. Dormant Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.1.1. Reasons for being dormant<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.2. Discontinued Products&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.2.1. Reasons for the discontinuation<\/span><\/p>\n<p style=\"text-align: justify;\"><span>17. Adrenoleukodystrophy &nbsp;Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>18. Adrenoleukodystrophy &nbsp;Future Perspectives<\/span><\/p>\n<p style=\"text-align: justify;\"><span>19. Adrenoleukodystrophy &nbsp;Analyst Review&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>20. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\"><span>21. Report Methodology<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=adrenoleukodystrophy-emerging-drugs-and-key-players-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=adrenoleukodystrophy-emerging-drugs-and-key-players-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP Adrenoleukodystrophy Pipeline Insight, 2020&#8243; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Adrenoleukodystrophy market. A detailed picture of the Adrenoleukodystrophy pipeline landscape is provided, which includes the disease &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/adrenoleukodystrophy-emerging-drugs-and-key-players-delveinsight_499847.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-499847","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=499847"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499847\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=499847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=499847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=499847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}